两剂灭活疫苗后科兴疫苗或ZF2001加强针的体液免疫原性和反应原性 - Suppr

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine.

作者信息

Cao Yunlong, Hao Xiaohua, Wang Xi, Wu Qianhui, Song Rui, Zhao Dong, Song Weiliang, Wang Yao, Yisimayi Ayijiang, Wang Wei, Zhang Wen, Du Juan, Yu Hongjie, Xie Xiaoliang Sunney, Jin Ronghua

机构信息

Changping Laboratory, Beijing, China.

Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.

出版信息

Cell Res. 2022 Jan;32(1):107-109. doi: 10.1038/s41422-021-00596-5. Epub 2021 Dec 3.

DOI:10.1038/s41422-021-00596-5

PMID:34862467

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8640508/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ef0/8724270/aa2c8c1cbda2/41422_2021_596_Fig1_HTML.jpg

相似文献

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine.两剂灭活疫苗后科兴疫苗或ZF2001加强针的体液免疫原性和反应原性

Cell Res. 2022 Jan;32(1):107-109. doi: 10.1038/s41422-021-00596-5. Epub 2021 Dec 3.

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series.在系统性红斑狼疮患者中使用异源加强针后，康希诺新冠疫苗的免疫原性、安全性和反应原性：一项病例系列研究。

RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-002019.

SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.两剂科兴疫苗接种方案后接种第三剂科兴疫苗或BNT162b2疫苗后的新冠病毒特异性抗体反应。

J Med Virol. 2022 Jan;94(1):39-41. doi: 10.1002/jmv.27350. Epub 2021 Sep 21.

Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.医护人员接种两剂灭活病毒疫苗后的免疫原性：有和无既往 COVID-19 感染的前瞻性观察研究。

J Med Virol. 2022 Jan;94(1):279-286. doi: 10.1002/jmv.27316. Epub 2021 Sep 10.

Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。

Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.

Booster doses for inactivated COVID-19 vaccines: if, when, and for whom.新冠病毒灭活疫苗的加强针：何时接种、针对哪些人群接种。

Lancet Infect Dis. 2022 Apr;22(4):430-432. doi: 10.1016/S1473-3099(21)00696-4. Epub 2021 Dec 8.

A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine.接种两剂新型冠状病毒灭活疫苗后，可能需要接种第三剂加强针以减轻中和抗体的衰减。

J Med Virol. 2022 Jan;94(1):35-38. doi: 10.1002/jmv.27334. Epub 2021 Sep 22.

mRNA COVID-19 Vaccine Booster After Inactivated Vaccine Primary Series.灭活疫苗基础免疫系列后接种新冠病毒mRNA疫苗加强针

JAMA. 2022 Jun 21;327(23):2280. doi: 10.1001/jama.2022.9408.

Immunogenicity, Reactogenicity, and Reinfection After 2 Doses of the Inactivated Whole-virion CoronaVac Vaccine in Kidney Transplant Recipients Convalescents From COVID-19.2剂灭活全病毒科兴疫苗对新冠康复期肾移植受者的免疫原性、反应原性及再感染情况

Transplantation. 2023 Feb 1;107(2):e72-e73. doi: 10.1097/TP.0000000000004439. Epub 2022 Nov 2.

Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents.白喉-破伤风-无细胞百日咳-灭活脊髓灰质炎疫苗与白喉-破伤风-灭活脊髓灰质炎疫苗加强剂量在青春期前儿童中的比较反应原性和免疫原性

Pediatr Infect Dis J. 1998 Sep;17(9):804-9. doi: 10.1097/00006454-199809000-00011.

引用本文的文献

Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants.抗SARS-CoV-2单克隆抗体SA55注射液在健康受试者中的安全性、耐受性和药代动力学

Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0056825. doi: 10.1128/aac.00568-25. Epub 2025 Jul 17.

An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters.一种RBD-Fc黏膜疫苗为小鼠和仓鼠提供了针对SARS-CoV-2的变异体抗性保护。

NPJ Vaccines. 2025 May 18;10(1):100. doi: 10.1038/s41541-025-01155-4.

Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial.新型嵌合型中国mRNA（RQ3013）SARS-CoV-2疫苗异源加强接种的有效性、免疫原性和安全性：一项随机、双盲、活性对照试验。

Hum Vaccin Immunother. 2025 Dec;21(1):2502250. doi: 10.1080/21645515.2025.2502250. Epub 2025 May 16.

Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial.一种改良型新冠mRNA疫苗SYS6006在健康成年人三剂灭活疫苗接种后作为第四剂加强针的安全性和免疫原性：一项开放标签的1期试验。

Life Metab. 2023 May 10;2(3):load019. doi: 10.1093/lifemeta/load019. eCollection 2023 Jun.

Induction of Fc-dependent functional antibodies against different variants of SARS-CoV-2 varies by vaccine type and prior infection.针对新冠病毒不同变体诱导产生依赖Fc的功能性抗体，其情况因疫苗类型和既往感染而有所不同。

Commun Med (Lond). 2024 Dec 19;4(1):273. doi: 10.1038/s43856-024-00686-6.

Linear ubiquitination mediates coronavirus NSP14-induced NF-κB activation.线性泛素化介导冠状病毒 NSP14 诱导的 NF-κB 激活。

Cell Commun Signal. 2024 Nov 30;22(1):573. doi: 10.1186/s12964-024-01949-4.

Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）从XBB到JN.1抗原性转变的抗体反应演变

Nature. 2025 Jan;637(8047):921-929. doi: 10.1038/s41586-024-08315-x. Epub 2024 Nov 7.

Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial.ZF2001 型重组新冠病毒疫苗（腺病毒载体）在 3-17 岁健康儿童和青少年中使用灭活疫苗基础免疫后的异源加强免疫的免疫原性和安全性：一项开放标签、单臂临床试验。

BMC Infect Dis. 2024 Apr 19;24(1):413. doi: 10.1186/s12879-024-09293-1.

The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality.SARS-CoV-2 的核衣壳蛋白与 ODN-39M 结合，是一种具有更广泛功能的鼻内双价疫苗的潜在成分。

Viruses. 2024 Mar 8;16(3):418. doi: 10.3390/v16030418.

An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza.一种鼻内联合疫苗可诱导针对新冠病毒和流感的全身及黏膜免疫。

NPJ Vaccines. 2024 Mar 21;9(1):64. doi: 10.1038/s41541-024-00857-5.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献